Connect Biopharma reports positive Phase 2 asthma, COPD data for rademikibart
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
1 story
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)